NATICK – Pillar Biosciences, a Natick-based sequencing (NGS) solutions in-vitro diagnostics (IVD) company, yesterday, September 1, announced the appointment of Randy Pritchard as Chief Executive Officer.
The company’s founder, industry veteran and renowned scientific innovator, Gang Song, Ph.D., will transition to the role of Chair of the Board, where he will be responsible for leading the Board, ensuring governance standard and focusing on all strategic matters for Pillar Biosciences.
In his new role as CEO, Pritchard will look to accelerate the company’s efforts to make precision oncology accessible for all patients throughout the patient journey.
Pritchard brings to Pillar Biosciences more than 24 years of healthcare experience, as a diagnostics executive who has deep experience in corporate and commercial strategy, sales and marketing, driving growth through innovation.
He has held positions of increasing responsibilities, including SVP of US Diagnostics marketing, SVP & Lifecycle Leader at the divisions of POC Diagnostic & Core Reagents, and VP of Marketing at Centralized Diagnostics at Roche Diagnostics.
“On behalf of the Board, I am excited to welcome Randy to lead Pillar Biosciences in its next stage of growth. He brings invaluable experience, as we accelerate our growth with the launch of our oncoReveal™ Dx Lung and Colon Cancer Assay, which received FDA Premarket Approval recently,” said Gang Song, Ph.D., Co-Founder and Chairman of the Board, Pillar Biosciences. “Pillar Biosciences was founded with a mission to make precision medicine accessible for all, by simplifying clinical next-generation sequencing (NGS) and bringing testing closer to the patient.”
“The Board was impressed by Randy’s depth of understanding of the diagnostics space and what drives growth, as well as his leadership experience,” said Simone Song, Founder, ORI Capital who has led repeated investments in Pillar Biosciences since its Series A financing. “His ability to quickly analyze a business, develop and execute on the growth strategy was truly remarkable. I am fully confident that Randy will be an outstanding leader for Pillar at this next stage of growth.”
“I look forward to working with Gang and the Pillar Biosciences team to accelerate the adoption of oncoReveal™ Dx and bring more innovative NGS cancer testing products to patients, in particular in the area of liquid biopsy,” said Randy Pritchard, CEO, Pillar Biosciences. “Pillar has grown to over 150 dedicated team members in the US and China, and I look forward to leading the company in its next stage of growth to become a global clinical cancer NGS diagnostics company.”
Pillar Biosciences is a global oncology solutions company delivering in-vitro diagnostics (IVD) that provide accurate, robust, timely, clinically actionable insights to guide treatment decisions throughout a patient’s continuum of care. Our mission is to enable access to high quality, affordable, specialty NGS testing, performed by any NGS laboratory as clinical grade tests, closer to home, for all patients. Pillar has operations in Natick, and Shanghai, China.